SELLAS Life Sciences Group Operating Income

SELLAS Life Sciences Group posts a operating income of $-31M as of March 2026. That compares with $-28M in the prior-year period — down 12.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, SELLAS Life Sciences Group's operating income was $-28M. The latest reading is $-31M — a 12.6% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of SELLAS Life Sciences Group's financial statement story. At $-31M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SLS's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; SELLAS Life Sciences Group's other metric pages and overview cover the third.

Judging SELLAS Life Sciences Group against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $-31M here, then scan peer and history charts to see if the gap is persistent.